GOLDEN, Colo., May 9, 2012 (GLOBE NEWSWIRE) — Vitro Diagnostics, Inc. (OTCQB:VODG.PK – News), dba Vitro Biopharma, announced the launch of a completely revised new website at www.vitrobiopharma.com. Vitro Biopharma is focused on providing unique tools for stem cell research and clinical development based on adult stem cells known as Mesenchymal Stem Cells or MSCs. These adult stem cells represent the fastest growing segment of the stem cell industry largely because of the availability of these cells from several tissue sources and the ever-increasing evidence for clinical effectiveness in the treatment of a variety of diseases, injuries and regenerative medicine applications. Vitro Biopharma is pleased to announce the launch of a completely revised and newly formatted website featuring E-commerce capabilities, a considerably expanded product offering, enhanced and readily accessible information for investors together with improved navigation, communication with the Company and ease of use.
Dr. Jim Musick, Vitro Biopharma’s President and CEO, said, “We are very pleased to announce the launch of our new robust website featuring online ordering from an expanded product menu & a fully integrated investor relations platform. We believe that E-commerce capabilities will expand our abilities to reach new customers, especially those customers located in other time zones. We are offering free shipping for all domestic orders. We are targeting key stem cell researchers and enhancing our abilities to deliver our products to them. The integration of our fully dynamic shopping cart allows Vitro to be competitive internationally. The investor relations platform will allow us to better communicate with our shareholders.
We have expanded our products that now include about 60 products by addition of new cell culture media formulations and additional stem cell products derived from differentiated stem cells including native and fluorescent-labeled cells for advanced studies of stem cell therapies. We also plan additional new product introductions in the near future to further expand our offerings to the markets we serve. We are continuously fostering collaborative relationships with our colleagues and customers to rapidly develop the potential of stem cell therapy into new treatment options for those patients who could benefit the most from these developments.”
To receive timely information on Vitro Biopharma, when it hits the newswire, sign up for Vitro Biopharma email news alert system today at: http://vitrobiopharma.com/ir_platform/email-alerts/
About Vitro Biopharma, Inc.
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB:VODG.PK – News) (http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro also owns a pending international patent for generation of pluripotent stem cells. Vitro’s mission is“Harnessing the Power of Cells(TM)” for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells “Tools for Stem Cell and Drug Development(TM)“, including human mesenchymal stem cells and derivatives, MSC-Gro(TM)optimized media for stem cell self-renewal and lineage-specific differentiation. Vitro has established a strategic alliance with HemoGenix(R), Inc. (http://www.hemogenix.com/) to jointly manufacture and distribute LUMENESC(TM) and LumiSTEM(TM) quantitative assays for determination of stem cell quality, potency and response to toxic agents. During 2011, the Company out-licensed its patents and related intellectual property for FSH generation and production to Dr. James Posillico, Ph.D., a global leader in women’s healthcare. FSH is a widely used hormone to treat infertility that continues to be a global health issue. The Company is actively assisting Dr. Posillico to develop distribution channels for therapeutic FSH into international markets.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.